RGNT Stock Chart & Stats
$4.03
-$0.54(-11.82%)
―
--
Day’s Range― - ―
52-Week Range$1.23 - $15.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)43.09K
Market Cap
$20.87M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,179,378
10 Day Avg. Volume10,866
30 Day Avg. Volume43,095
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Regentis Biomaterials Ltd News
RGNT FAQ
What was Regentis Biomaterials Ltd’s price range in the past 12 months?
Regentis Biomaterials Ltd lowest stock price was $1.23 and its highest was $15.50 in the past 12 months.
What is Regentis Biomaterials Ltd’s market cap?
Regentis Biomaterials Ltd’s market cap is $20.87M.
When is Regentis Biomaterials Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Regentis Biomaterials Ltd’s earnings last quarter?
Currently, no data Available
Is Regentis Biomaterials Ltd overvalued?
According to Wall Street analysts Regentis Biomaterials Ltd’s price is currently Undervalued.
Does Regentis Biomaterials Ltd pay dividends?
Regentis Biomaterials Ltd does not currently pay dividends.
What is Regentis Biomaterials Ltd’s EPS estimate?
Regentis Biomaterials Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regentis Biomaterials Ltd have?
Regentis Biomaterials Ltd has 5,179,378 shares outstanding.
What happened to Regentis Biomaterials Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Regentis Biomaterials Ltd?
Currently, no hedge funds are holding shares in RGNT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Regentis Biomaterials Ltd
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Ownership Overview
―
Insiders
―
Mutual Funds
10.65% Other Institutional Investors
89.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---